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Abbreviations
and Acronyms
CI = conﬁdence interval(s)
EOA = effective oriﬁce area
HR = hazard ratio(s)
ITT = intention-to-treat
analysis
LV = left ventricular
LVDV = left ventricular
diastolic volume
LVED = left ventricular
end-diastolic dimensions
LVES = left ventricular
end-systolic dimensions
LVSV = left ventricular
systolic volume
RWT = relative wall
thickness
RWTm = relative wall
thickness: the septal and
posterior wall thickness
RWTp = relative wall
thickness: using formula
twice the posterior wall
thickness
SAVR = surgical aortic valve
replacement
TAVR = transcatheter aortic
valve replacement
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2515operable patients with severe aortic stenosis (PARTNER
Cohort A) showed TAVR was noninferior to SAVR with-
out signiﬁcant differences in all-cause mortality or cardio-
vascular mortality or evidence for structural valve failure.
See page 2522
Echocardiography is the recommended imaging modality
for the assessment of aortic valve stenosis and prosthetic valve
function (5–7) and was used for patient selection, valve sizing,
and extended follow-up (1,2). In contrast to previous reports
relying on site interpretations of images, the trial core labo-
ratory provided rigorous quality control of the image ac-
quisition and analysis process (8). The current investigation
reports the complete, centrally analyzed echocardiographic
ﬁndings from the high-risk, operable patient population
(Cohort A).
Methods
Patient selection, study design, and management. Co-
hort A of the PARTNER trial (2) randomized 699 high-
surgical-risk patients (mortality of 15%) with severe,
symptomatic aortic stenosis, between SAVR and TAVRwith
the Edwards Sapien valve (Edwards Lifesciences, Irvine,
California) (in a 1:1 ratio) (Fig. 1). All patients enrolled had
site-determined, severe native tricuspid aortic stenosis
deﬁned by echocardiographically determined aortic valve area
of 0.8 cm2 plus either a peak velocity 4 m/s or a mean
gradient 40 mm Hg at rest or during dobutamine infusion.
Study design and complete inclusion and exclusion criteria are
presented in a previous publication (2).
Randomization to SAVR or TAVR was stratiﬁed by feasi-
bility of transapical or transfemoral access. Echocardiograms
were obtained at baseline, and at 7 days, 30 days, 6 months, 1
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toryanalysis. All echocardiograms
were analyzed at an independent
core lab that followed theAmerican
Society of Echocardiography stan-
dards for echocardiography core
laboratories (9). Image acquisition
quality was ensured by use of
a detailed acquisition protocol, site
qualiﬁcation and training with
quality feedback at regular inter-
vals, and retraining of sites with
unacceptable image quality. Image
analysis quality was ensured by
reader qualiﬁcation, detailed anal-
ysis instructions, group and indi-
vidual training, regular intra- and
interobserver variability testing,
retraining, and coaching when
indicated (9). All measurements
and analyses were performed
without knowledge of clinical
or other laboratory data including
previous echocardiography results,
group assignment, and timing of
the assessment.
Reproducibility was determined
on 649 to 1,360 pairwise compar-
isons among readers for each of 8
critical variables on 30 echocardiograms (total number of
comparisons ¼ 8,031). Intraclass correlation coefﬁcients were
0.92 to 0.99 for physician over-readers and 0.89 to 0.97 for
sonographers. Kappa statistics for agreement for categorical
variables calculated for physician over-readers were 0.56 to
0.85.
Ventricular size and function and valvular function were
measured according to previously published guidelines
(6,7,10). An integrative, semiquantitative approach was used
to assess the severity of valvular regurgitation. Both qualita-
tive (visual) and quantitative (biplane Simpson method of
disks) approaches were used to report ejection fraction.
Relative wall thickness (RWT) was calculated as 2 poste-
rior wall thickness/left ventricular end-diastolic dimensions
(LVED) (RWTp) and also using the posterior wall thickness
plus septal wall thickness as (septal wall thickness þ posterior
wall thickness)/LVED, or RWTm. Site-reported systolic
annulus diameters were derived from long-axis views. The
effective oriﬁce area (EOA) is calculated as the Doppler
stroke volume/aortic velocity time integral. The cover index
was determined as (11): [prosthesis diameter – annular
diameter]/prosthesis diameter. The severity of prosthesis-
patient mismatch was graded using EOA indexed to body
surface area (6) with absence deﬁned as >0.85 cm2/m2,
moderate 0.65 and 0.85 cm2/m2, and <0.65 cm2/m2.
Paravalvular regurgitation after TAVR/SAVR was graded
in accordance with the ASE recommendations for native
Figure 1 Flowchart of High-Risk PARTNER Trial
(A) Flow chart of patient randomization and follow-up for Cohort A of the PARTNER (Placement of Aortic Transcatheter Valves) trial. (B) Outline of the intention-to-treat (ITT) and as-
treated patient population of Cohort A. *Reasons for exclusion included: valve embolization (n¼ 5), TEE ﬁndings (n¼ 5), access problems (n¼ 5), death prior to valve deployment
(n¼2), largesigmoidseptum (n¼1). yReasons for exclusion: porcelainaorta (n¼1) andmediastinal adhesions (n¼1). AVR¼aortic valve replacement; LTF¼ lost to follow-up; pts¼
patients; SAVR¼ surgical aortic valve replacement; TA¼ transapical; TAVR¼ transcatheter aortic valve replacement; TEE¼ transesophageal echocardiography; TF¼ transfemoral.
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2516valves (12) and adoption of the 2009 prosthetic valve
guidelines (6) with the following exception. Because of the
eccentric, irregular, jet and the frequent noncylindrical
“spray” of the paravalvular jet contour, the parasternal short-
axis view(s) was weighted more heavily than other signals in
providing an integrated assessment, as follows: none ¼ no
regurgitant color ﬂow; trace ¼ pinpoint jet in aortic valve;
mild ¼ jet arc length is <10% of the annulus circumference;
moderate ¼ jet arc length is 10% to 30% of the annulus
circumference; severe ¼ jet arc length is >30% of the
annulus circumference.
Statistical methods. Analysis is based on the actual valve
implant patients who received and retained either a surgical
or transcatheter valve, as this group is most appropriate for
studying the echocardiographic measurements and out-
comes. Intention-to-treat analysis (ITT) for evaluating trial
endpoints has previously been reported (2,4). Because of the
difﬁculty in imaging patients immediately following inter-
vention, the ﬁrst post-implantation values are obtained from
the ﬁrst available value at discharge, 30 days, or 6 months.
Categorical variables were compared using Fisher exact
test. Because regurgitation and prosthesis-patient mismatch
are ordinal variables, comparisons involving these variables
use the exact Jonckheere-Terpstra test. It should be noted
that when 1 of the variables has 2 levels, the test is equivalent
to the exact Mann-Whitney U test; where both have >2
levels, the use of the Jonckheere-Terpstra test is important.
Continuous variables were presented as mean  SD and
were compared using Student t test; comparisons with
baseline values use the paired sample Student t test. Survival
curves for time-to-event variables were constructed using
Kaplan-Meier estimates based on all available data and were
compared using the log-rank test. To study the impact ofrisk factors on mortality, Cox proportional hazards regres-
sion was performed.
Imputation was not performed for missing baseline or ﬁrst
post-implantation variables except in the multivariable
models. The effect is that patients whose values are missing
for a particular analysis are removed from that analysis.
Data are based on an extract date of February 13, 2012.
All statistical analyses were performed in SAS software
(version 9.2, SAS Institute, Cary, North Carolina).
Results
In the ITT TAVR arm, there were 348 randomized
patients; 344 were as-treated TAVR and 326 were valve
implantations of which 97 used transapical and 229 used
transfemoral approaches. In the ITT SAVR arm, there were
351 randomized patients; of these 313 were as-treated
SAVR and 310 were valve implantations (Fig. 1). Patients’
baseline clinical demographics using the ITT populations
are listed in Online Table 1. There were no statistically
signiﬁcant differences between the groups, except there were
more patients with high creatinine in the TAVR group.
Baseline echocardiographic parameters. There were no
baseline differences in left ventricular (LV) size, geometry,
and function between as-treated SAVR and TAVR groups
(Online Table 2). The 2 groups were similar in LVED, left
ventricular end-systolic dimensions (LVES), RWTp and
RWTm, left ventricular mass, left ventricular mass index,
left ventricular diastolic volume (LVDV), left ventricular
systolic volume (LVSV), and LV stroke volume as well as
calculated ejection fraction.
Baseline valvular hemodynamics have previously been re-
ported (4) and are summarized in Online Table 2. There
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2517were no signiﬁcant differences between SAVR and TAVR
groups for baseline peak velocity, peak gradient, mean
gradient, stroke volume–calculated (by any method) aortic
valve area, or aortic valve area index. There was no signiﬁcant
difference in the severity of mitral or aortic regurgitation.
Ventricular and valvular changes immediately following
intervention. In the TAVR cohort (Online Table 3),
neither LVED nor LVDV changed immediately after
intervention; however, LVES (p ¼ 0.0005) and LVSV
(p ¼ 0.0016) were signiﬁcantly smaller and ejection fraction
was higher (p < 0.0001). Peak and mean aortic valve
gradients decreased (p < 0.0001) and EOA increased
(p < 0.0001). There was a signiﬁcant reduction in mitral
regurgitation (p < 0.0001) with no change in total aortic
regurgitation (p ¼ 0.649).
In the SAVR cohort there was a signiﬁcant decrease in
LVED, LVDV, LVES, and LVSV immediately following
intervention (Online Table 3), associated with reduced stroke
volume by 2-dimensional echocardiography (p< 0.0001) and
Doppler echocardiography (p < 0.0001), but no change in
ejection fraction. Peak and mean aortic valve gradients
decreased (p< 0.0001) with an increase in EOA (p< 0.0001).
There was a signiﬁcant reduction in both mitral regurgitation
and aortic regurgitation (p < 0.0001).
Comparison of SAVR and TAVR. Online Table 4 com-
pares TAVR and SAVR baseline and post-implantation
echocardiographic variables of ventricular size and func-
tion. TAVR as compared to SAVR had a signiﬁcantly larger
LVED up to 6 months following valve replacement, but not
after 1 or 2 years of follow-up. LVDV showed inconsistent
differences, neither LVES nor LVSV showed between-Figure 2 Incidence of Prosthesis-Patient Mismatch
The incidence of prosthesis-patient mismatch (percentage) in the TAVR and SAVR patien
follows: Insigniﬁcant is an indexed effective oriﬁce area (EOA) >0.85 cm2/m2; moderate
EOA of <0.65 cm2/m2. Abbreviations as in Figure 1.group differences throughout follow-up. LV mass and LV
mass index were larger in the TAVR patients at discharge,
6 months, and 1 year, but not at 2 years. The percentage of
LV mass reduction was initially greater for the SAVR group,
but was not signiﬁcantly different after 6 months. RWTp
and RWTm following valve replacement were initially
higher for the SAVR group but progressively decreased for
both groups.
Although 2-dimensional echocardiography stroke volume
showed inconsistent differences at various times, Doppler
stroke volume was signiﬁcantly larger in TAVR patients up
to 2 years, at which time there was no signiﬁcant difference.
There was no signiﬁcant between-group difference in ejec-
tion fraction throughout follow-up.
Online Table 5 compares the baseline and post-implan-
tation echocardiographic variables of valvular function, for
TAVR versus SAVR groups. Peak and mean transaortic
gradients were signiﬁcantly lower in the TAVR group for
most follow-up times. EOA and indexed EOA were
signiﬁcantly larger in TAVR at all follow-up times.
Prosthesis-patient mismatch was more common in the
SAVR group throughout follow-up (Fig. 2, Online Table 6).
There were no signiﬁcant differences in mitral regurgitation
between TAVR and SAVR groups up to 2 years (Fig. 3,
Online Table 5).
TAVR patients had signiﬁcantly more total aortic regur-
gitation at every post-implantation time than did patients in
the SAVR cohort (Online Tables 5 and 7). Mild, moderate,
or severe paravalvular aortic regurgitation (Fig. 4, Online
Table 8) was more common in the TAVR group at every
follow-up time (p < 0.0001).t populations is shown. The deﬁnition for prosthesis-patient mismatch is as
is an indexed EOA of 0.65 cm2/m2 and 0.85 cm2/m2; severe is an indexed
Figure 3 Mitral Regurgitation Prevalence
The comparison of mitral regurgitation severity in the TAVR versus SAVR patient populations is shown at various follow-up times. The only signiﬁcant between-group difference
was seen at the 1-year point with no signiﬁcant difference at any other time. NS ¼ not signiﬁcant; other abbreviations as in Figure 1.
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2518There were no cases of structural valve failure or migration
of the valve after initially successful implantation in either
group.
Within-group changes over time. Online Tables 4 and 5
show within-group changes over the 2-year follow-up
period. Both groups showed a continuous reduction in
RWT and LV mass or LV mass index over time. After anFigure 4 Paravalvular Aortic Regurgitation Incidence
The incidence of paravalvular aortic regurgitation in the TAVR versus SAVR patient popula
noted. There is signiﬁcantly more aortic regurgitation in the TAVR group at every point. Ainitial fall in Doppler stroke volume in the SAVR group,
both groups showed signiﬁcant increases in stroke volume
over time. The TAVR group showed an immediate increase
in ejection fraction following intervention with no change up
to 2 years. The SAVR group showed no immediate increase
in ejection fraction but a signiﬁcant increase at 2 years. Both
groups showed immediate reduction in peak and meantions is shown at various follow-up times with p values for between-group differences
bbreviations as in Figure 1.
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2519transaortic gradients with slight further reductions over time.
Both groups showed a sustained, stable increase in EOA and
indexed EOA.
Aortic regurgitation. Following intervention, there was no
signiﬁcant change in total aortic regurgitation in the TAVR
group, and an immediate reduction in the SAVR group
followed by a slight increase in aortic regurgitation over time
(Online Table 5). Mitral regurgitation severity was reduced
in both groups following intervention but showed a slight
increase from immediate post-intervention levels by 2 years.
In the TAVR group, paravalvular aortic regurgitation
remained unchanged in 45.4% of patients, improved in
31.9%, and worsened in 22.7% of patients. Seven patients
worsened from none/trace/mild to moderate following
intervention. Conversely, 8 patients improved from moderate
to none/trace/mild. No patient developed new severe aortic
regurgitation. There was no signiﬁcant baseline patient
clinical differences between patients with none/trace
or mild paravalvular aortic regurgitation (Online Table 9);
however, there were signiﬁcant differences in echocardio-
graphic measures of ventricular size and function. Patients
with mild paravalvular aortic regurgitation had larger
baseline measurements of aortic annular dimensions
(p ¼ 0.040), LVED (p ¼0.008), LVDV (p ¼ 0.019), LV
mass (p ¼ 0.003), and LV mass index (p ¼ 0.007). Baseline
ejection fraction was also lower in the mild paravalvular
aortic regurgitation group. A greater number of patients
with mild paravalvular aortic regurgitation had low
stroke volume (35 ml/m2) at baseline. There were no
signiﬁcant differences in baseline gradients or valve area.
There was no impact of the prosthesis size on severity of total
aortic regurgitation (none, trace, mild, moderate, or severe)
(p ¼ 0.38, not shown) or paravalvular aortic regurgitation
following TAVR (Online Table 9).
Following TAVR, patients with mild paravalvular aortic
regurgitation had larger values for ﬁrst post-implantation
LVED (p ¼ 0.009), LVDV (p ¼ 0.003), LV mass
(p ¼ 0.001), and LV mass index (p ¼ 0.007). There was no
difference in ﬁrst post-implantation ejection fraction,
transaortic gradients, EOA, prosthesis-patient mismatch, or
implanted valve size. There was a higher frequency of low
cover index (<8%) in patients with mild paravalvular aortic
regurgitation (p ¼ 0.012). There was a signiﬁcantly higher
2-dimensional echocardiography and Doppler stroke volume
in the mild paravalvular aortic regurgitation group.
Echocardiographic variables associated with outcome.
Univariate echocardiographic determinants of mortality in
the TAVR group were evaluated (Online Table 10). The
only baseline echocardiographic univariate predictor of
death in the TAVR group was baseline peak gradient
(hazard ratio [HR]: 0.94, 95% conﬁdence interval [CI]: 0.90
to 0.99, per 5 mm Hg increase, p ¼ 0.010). After implan-
tation, there were a number of echocardiographic univariate
predictors of death in the TAVR group, the strongest of
which was mild paravalvular aortic regurgitation (HR:
2.11, 95% CI: 1.43 to 3.10, p ¼ 0.0002). Other post-TAVRpredictors of mortality include larger LVDV, LVSV and
indexed EOA, and lower ejection fraction. The presence of
prosthesis-patient mismatch (indexed EOA <0.85 cm2/m2)
was a predictor of decreased mortality (HR: 0.736, 95%
CI: 0.57 to 0.96, p ¼ 0.024).
There were many baseline univariate echocardiographic
determinants of mortality in the SAVR group (Online
Table 11), the strongest of which was mitral regurgitation
(HR: 1.49, 95% CI: 1.17 to 1.90, per 1 grade, p ¼ 0.001).
After valve replacement, the strongest univariate echocar-
diographic predictors of death were the presence of low
stroke volume (35 ml/m2) (HR: 1.97, 95% CI: 1.16 to
3.33, p ¼ 0012) and prosthesis-patient mismatch (HR:
1.43, 95% CI: 1.11 to 1.84, p ¼ 0.005). Other post-SAVR
predictors of mortality include smaller LVDV, LVSV,
EOA, and stroke volume.
Discussion
Cohort A of the PARTNER trial is the ﬁrst large
randomized trial showing comparable outcomes of SAVR
and TAVR in high-risk, operable patients with severe
symptomatic aortic stenosis (4). The present study reports
the centrally analyzed echocardiographic data comparing
SAVR and TAVR, which document early and sustained
hemodynamic improvements with both therapies, and
freedom from structural valve deterioration, while high-
lighting the differences in therapeutic groups, and present-
ing echocardiographic determinants of outcome.
Valve performance. Improvements in valve area and mean
gradients are sustained over the 2-year interval reported
with no evidence of stent recoil in the TAVR group. No
structural valve dysfunction was found out to 2 years in
either arm of this study. The current study thus highlights
the 2-year durability of the Edwards Sapien balloon-
expandable valve.
Ventricular remodeling and function. Following valve
replacement, there is substantial ventricular remodeling with
reduction in RWT and LV mass in both groups. The SAVR
group had more absolute LV mass regression early; however,
there was no difference in mass regression rates over the
follow-up period between SAVR and TAVR. Factors other
than valve area may adversely inﬂuence LV remodeling
including more aortic regurgitation (in the TAVR pop-
ulation) or concomitant surgical procedures (mitral valve
repair/replacement or coronary bypass performed as protocol
violations in the SAVR population).
Ejection fraction improves early following TAVR and
later during follow-up in the SAVR group with no signiﬁ-
cant difference by 2 years. Because LVED, LVES, and
mitral regurgitation are not signiﬁcantly different between
groups, the larger stroke volumes in the TAVR group
support the qualitative ﬁnding of greater aortic regurgitation.
Other factors that could inﬂuence LV remodeling (i.e.,
hypertension, renal dysfunction, sex) and ventricular func-
tion warrant further study.
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2520Factors associated with outcome. The TAVR and SAVR
groups had different univariate factors associated with
outcome. In the TAVR group, only baseline low peak
gradients, possibly in the setting of low stroke volume,
predicted worse outcome. Post-TAVR, larger LV volumes
(either systolic or diastolic) and lower ejection fractions
determined worse outcome; how this may be related to aortic
regurgitation is unknown. In the SAVR group, baseline or
post-SAVR small LVED volume and low stroke volume are
associated with increased mortality. The strongest predictor
of mortality was baseline severity of mitral regurgitation. Six
patients had concomitant mitral surgery (a protocol viola-
tion), and how this might inﬂuence outcomes requires
further investigation.
Similar to previous studies (13), our study conﬁrms that
prosthesis-patient mismatch has a negative effect on survival
in the SAVR population. Also similar to prior studies (14),
indexed EOA in the TAVR groups is larger than it is in the
SAVR group despite comparable annular dimensions.
Counterintuitively, univariate analysis of the TAVR group
had a lower mortality in the presence of prosthesis-patient
mismatch. This ﬁnding might be driven by body size,
because in the TAVR cohort, body mass index was also
associated with lower mortality (Online Table 10).
Conversely, this ﬁnding may also be driven by a population
of patients with a small annulus; patients with a small aortic
annulus have better outcomes with TAVR than with SAVR
(15,16). In addition, a small annulus in the TAVR pop-
ulation has been associated with less paravalvular aortic
regurgitation (11). Further multivariable modeling should be
performed.
Aortic regurgitation. Recent surgical studies suggest par-
avalvular regurgitation following SAVR occurs in 10% to
48% of patients (17–22) and even mild paravalvular regur-
gitation has a negative impact on survival (23). The current
study conﬁrms a high incidence of aortic regurgitation in the
SAVR group (50%); however, only 14% have mild para-
valvular aortic regurgitation.
Our study supports other studies (13,24–26) showing
a signiﬁcant relationship between mortality and paravalvular
aortic regurgitation in TAVR patients. Despite the inherent
limitations of the current grading method for paravalvular
regurgitation, it has been shown to predict outcomes (4),
which provides indirect validation. Further validation of this
grading scheme against other quantitative assessments of
severity of regurgitation should be performed. Finally,
differences in the baseline characteristics between groups
with paravalvular aortic regurgitation might have contrib-
uted to the increased mortality.
Study limitations. We used the site-speciﬁed systolic
annular measurement because: 1) most were from intra-
procedural transesophageal echocardiograms and likely
more accurate than transthoracic measurements; and 2)
the measurement was performed in systole (whereas as per
previously published guidelines (10), the echocardio-
graphic core laboratory performed aorta measurements indiastole). In the PARTNER trial, a systolic, sagittal plane
systolic annulus was used for sizing the transcatheter heart
valve.
Whenever possible, we evaluated paired echocardio-
graphic data; however, longitudinal differences between
groups with high mortality rates may introduce survivorship
bias. Finally, echocardiographic measurements are depen-
dent on image quality as well as inter- and intraobserver
variability. Use of an echocardiographic core laboratory
should limit this variability as has been demonstrated
previously for the PARTNER trial (8); however, limited
echocardiographic measurability may introduce another
form of bias. In addition, several variable comparisons have
been made in the manuscript, and no adjustment has been
made for the multiple comparisons.
For the “ﬁrst post-implantation” measurement, discharge
or 30-day values were used in 90% to 96% of ventricular
size and function measurements, and 99% of Doppler
measurements; 6 month data were rarely used.
The limitations of paravalvular aortic regurgitation
grading have been discussed but remain a signiﬁcant issue
for both surgical and transcatheter valves. It is important to
note that the circumferential extent grading scheme used
differs slightly from the upper cut point of 20% for moderate
paravalvular regurgitation recommended by the 2009
American Society of Echocardiography/European Associa-
tion of Echocardiography guidelines (6), which were pub-
lished after the PARTNER analysis plan was established.
Advanced echocardiographic techniques, such as 3-di-
mensional color Doppler echocardiography or quantitative
methods, as well as intraprocedural studies were not evaluated.Conclusions
This study is the ﬁrst to use centrally analyzed echocardio-
graphic data to compare the structural and hemodynamic
results in high-risk patients with symptomatic severe aortic
stenosis randomized to SAVR or TAVR. Immediately
following valve replacement, both groups showed a signiﬁ-
cant reduction in transaortic gradients and an increase in
EOA with similar LV mass regression and remodeling over
time. However, indexed EOA was consistently higher and
prosthesis-patient mismatch lower in the TAVR group
throughout the follow-up period. The intermediate-term
durability of the Edwards Sapien valve is comparable to
SAVR. Survival was strongly affected by low stroke volume
and prosthesis-patient mismatch in the SAVR cohort and
post-intervention aortic regurgitation in the TAVR cohort.
A complete understanding of these differences may allow
future reﬁnement in patient selection.
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